Vitamin d and malaria drug join forces against pancreatic cancer
NCT ID NCT04524702
First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 11 times
Summary
This study tested whether adding two drugs—paricalcitol (a form of vitamin D) and hydroxychloroquine (a malaria drug)—to standard chemotherapy could help shrink tumors in people with advanced pancreatic cancer that has spread. Ten participants received the combination treatment. The goal was to see if the tumor response rate improved compared to chemo alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory Saint Joseph's Hosptial
Atlanta, Georgia, 30342, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.